GlaxoSmithKline Signs Global Software Agreement with Desert Scientific Software

GlaxoSmithKline has licensed Desert Scientific Software’s, Proasis2, protein structure database and visualisation system.

Desert Scientific Software (DesertSci), a chemo/bioinformatics software company based in Sydney, Australia is pleased to announce the global licensing of their flagship product, Proasis2, by GlaxoSmithKline (GSK). The collaboration includes further development and implementation of customised new features.

Proasis2 is a state of the art protein structure database and visualization system. It is a web-based tool designed specifically for drug discovery research. Developed in collaboration with a number of global pharmaceutical companies, the software makes the access to protein structures for molecular visualisation and modelling applications as routine as searching the internet. It empowers chemists to explore their own drug design ideas and increases the productivity of expert modellers.

Dr. Neil Taylor, Founder and Chief Scientific Officer of Desert Scientific Software said “We have a commitment to providing software tools that optimize the efficiency of individual scientists and facilitate the dissemination of expertise within research groups.”

Click here to learn more about Proasis2